Anagenics Ltd

Consumer Defensive AU AN1

0.008AUD
-(-%)

Last update at 2024-11-11T23:00:00Z

Day Range

0.0080.008
LowHigh

52 Week Range

0.0060.03
LowHigh

Fundamentals

  • Previous Close 0.008
  • Market Cap3.69M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.23449M
  • Revenue TTM10.80M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 4.41M
  • Diluted EPS TTM-0.02

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -2.19644M -3.64400M -3.75989M -4.81782M -5.88544M
Minority interest - - - - -
Net income -2.66715M -3.64879M -3.38663M -4.90730M -5.90956M
Selling general administrative 4.12M 5.85M 0.06M 5.18M 5.38M
Selling and marketing expenses 1.75M 2.38M 5.89M 2.02M 1.71M
Gross profit 4.05M 5.07M 3.70M 4.85M 5.16M
Reconciled depreciation 0.36M 0.49M 0.45M 0.52M 0.15M
Ebit -1.91746M -2.29851M -3.06815M -4.74657M -5.65040M
Ebitda -1.55764M -1.80383M -2.61563M -4.22791M -5.31555M
Depreciation and amortization 0.36M 0.49M 0.45M 0.52M 0.33M
Non operating income net other - - - - -
Operating income -1.91746M -2.29851M -3.06815M -4.74657M -5.65040M
Other operating expenses 11.03M 13.80M 10.34M 13.81M 14.33M
Interest expense 0.03M 0.07M 0.05M 0.07M 0.24M
Tax provision 0.00787M 0.00478M 0.05M 0.09M 0.02M
Interest income 0.02M 0.03M 0.02M 0.02M 0.08M
Net interest income -0.00958M -0.04152M -0.03148M -0.05150M -0.15817M
Extraordinary items -0.92546M -2.00532M 0.42M -0.55080M -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.45475M 0.00478M 0.05M 0.09M 0.02M
Total revenue 9.11M 9.23M 5.82M 7.38M 7.30M
Total operating expenses 5.97M 9.63M 8.23M 11.28M 12.20M
Cost of revenue 5.06M 4.17M 2.11M 2.53M 2.14M
Total other income expense net -0.27898M 0.46M 0.34M 1.15M 0.97M
Discontinued operations -0.92546M -2.00532M 0.42M -0.55080M -0.55080M
Net income from continuing ops -1.74169M -3.64879M -3.80493M -4.90730M -5.90956M
Net income applicable to common shares -2.66715M -3.64879M -3.38663M -4.90730M -5.90956M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 6.45M 11.11M 12.92M 13.29M 14.89M
Intangible assets - 0.00144M 0.02M 1.43M 1.76M
Earning assets - - - - -
Other current assets 0.32M 0.05M 0.12M 0.22M 0.18M
Total liab 3.74M 2.22M 4.64M 2.86M 5.08M
Total stockholder equity 2.71M 8.90M 8.29M 10.43M 9.81M
Deferred long term liab - - - - -
Other current liab 0.23M 0.59M 2.25M 0.64M 2.18M
Common stock 66.83M 65.36M 62.44M 60.28M 56.06M
Capital stock - 65.36M 62.44M 60.28M 56.06M
Retained earnings -64.06175M -56.56854M -53.90139M -50.77746M -47.39082M
Other liab - 0.04M 0.12M 0.10M 0.10M
Good will 1.95M 3.45M 3.45M - -
Other assets 0.00000M 0.58M - - -
Cash 1.62M 2.57M 3.28M 6.73M 6.97M
Cash and equivalents - 2.57M 3.28M 6.73M 6.97M
Total current liabilities 3.43M 1.71M 3.66M 1.92M 3.48M
Current deferred revenue 0.40M - - - -
Net debt -0.85128M - -1.52774M -5.29392M -5.00950M
Short term debt 0.47M 0.00000M 0.90M 0.59M 0.47M
Short long term debt - - 0.56M 0.34M 0.22M
Short long term debt total 0.77M - 1.76M 1.43M 1.96M
Other stockholder equity -0.00000M 0.11M -0.24408M 0.93M 1.14M
Property plant equipment - 0.77M 0.58M 0.53M 1.50M
Total current assets 4.09M 6.25M 8.77M 11.29M 11.63M
Long term investments - - - - -
Net tangible assets - 5.38M 4.71M 8.96M 8.05M
Short term investments - - - - -
Net receivables 0.67M 1.04M 0.92M 1.80M 1.87M
Long term debt - 0.00000M 0.77M 0.60M 1.03M
Inventory 1.48M 2.40M 4.45M 2.55M 2.61M
Accounts payable 2.33M 0.72M 0.50M 0.68M 0.84M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.05958M - -0.24408M 0.93M 1.14M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00144M 0.58M - - -
Deferred long term asset charges - - - - -
Non current assets total 2.36M 4.86M 4.15M 2.01M 3.26M
Capital lease obligations - 0.65M 0.43M 0.49M 0.71M
Long term debt total - 0.46M 0.85M 0.84M 1.34M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -1.50875M -0.96820M 0.48M - -0.06568M
Change to liabilities -0.18285M -1.07450M -0.43682M 0.00042M 1.18M
Total cashflows from investing activities -1.50875M -0.96820M 0.48M 0.48M -0.06568M
Net borrowings -0.34279M 0.10M -0.57939M -0.26002M -1.98745M
Total cash from financing activities 2.56M 0.07M 3.50M 7.98M 7.27M
Change to operating activities -0.12585M -0.15575M -1.00844M 0.39M 0.05M
Net income -1.74169M -1.64347M -3.38663M -4.90730M -5.90956M
Change in cash -0.71779M -3.44291M -0.24320M 3.89M 1.47M
Begin period cash flow 3.28M 6.73M 6.97M 3.08M 1.61M
End period cash flow 2.57M 3.28M 6.73M 6.97M 3.08M
Total cash from operating activities -1.78049M -2.54934M -4.11415M -4.01311M -5.93466M
Issuance of capital stock 3.18M - 4.51M 8.85M 10.11M
Depreciation 0.36M 0.38M 0.43M 0.52M 0.15M
Other cashflows from investing activities -0.61978M -0.93226M 0.50M 0.50M 0.50M
Dividends paid 0.27M - 0.05M 0.20M -
Change to inventory 0.04M 0.28M -0.27416M -0.99095M -0.35537M
Change to account receivables -0.05269M 1.32M -0.05973M 0.32M -1.25533M
Sale purchase of stock -0.27143M 0.00000M -0.37899M -0.53583M -0.11479M
Other cashflows from financing activities 0.22M 0.63M -0.26064M -0.03102M -0.26329M
Change to netincome 0.87M 0.26M 0.60M 0.66M 0.46M
Capital expenditures 0.05M 0.04M 0.02M 0.02M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.31925M 0.37M 0.93M 1.01M -0.37632M
Stock based compensation 0.02M 0.22M 0.16M 0.46M 0.32M
Other non cash items 0.83M -1.42595M 1.69M 1.74M 0.93M
Free cash flow -1.82586M -2.58529M -0.02247M -4.01311M -6.00034M

Peer Comparison

Sector: Consumer Defensive Industry: Household & Personal Products

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AN1
Anagenics Ltd
- -% 0.008 - - 0.34 1.36 0.26 -3.9793
MCP
Mcpherson'S Ltd
0.02 5.26% 0.40 - 16.08 0.39 0.63 0.35 16.32
S66
Star Combo Pharma Ltd
- -% 0.11 - - 0.67 0.53 0.49 6.14
PTL
Prestal Holdings Limited
0.007 8.64% 0.09 - - 0.67 0.50 0.52 5.04
ZNO
Zoono Group Ltd
-0.002 7.41% 0.03 - - 8.81 1.48 8.51 -1.3808

Reports Covered

Stock Research & News

Profile

Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Anagenics Ltd

55 Clarence Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Matthew Dudek Acting Chief Exec. Officer NA
Mr. Dominic Burg Chief Operating Officer NA
Ms. Carolyn Heath Chief Customer Officer & GM of Sales NA
Dr. Graham Robertson Head of R&D NA
Mr. Scott Mitchell Greasley Exec. Director NA
Mr. Lee Tamplin B.A. Company Sec. NA
Mr. Scott Mitchell Greasley CEO, MD & Executive Director NA
Mr. Matthew Dudek Chief Financial & Governance Officer and Company Secretary NA
Dr. Graham Robertson Head of Research & Development NA
Mr. Scott Mitchell Greasley CEO, MD & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.